

FMC Corporation
1735 Market Street
Philadelphia Pennsylvania 19103
215 299 6000

MR 507
8EHQ - 0898 - 14171S



CERTIFIED MAIL
RETURN RECEIPT REQUESTED

August 6, 1998

8EHQ-98-14171

89980000 2805

Document Control Office (7407)
Room G99 East Tower Waterside Mall
USEPA/OPPT
401 M. Street, S.W.
Washington, D.C. 20460-0001

RECEIVED
OPPT/CBIC
98 AUG 11 AM 11:12

ATTN: TSCA Section 8(e)

Re: 8EHQ-0498-14170S and
8EHQ-0498-14171S

Dear Sir:

On April 24, 1998, FMC Corporation notified EPA, pursuant to TSCA 8(e), of substantial risk information relative to two toxicity studies (as referenced above) conducted with a FMC generically known as N-amino aryluracil. In that submission, FMC claimed the chemical identity and use as Confidential. Substantiation of those claims were submitted on May 18, 1998.

Quite recently, on July 30, 1998, I received a letter from Richard Hefter requesting "information on uses and other available exposure information" on the above cited chemical. This chemical, as mentioned in our CBI Substantiation letter, is a Research and Development chemical which was synthesized by our FMC has recently made the decision not to develop this chemical for commercialization. No further studies are intended to be conducted nor is any type of testing scheduled.

COMPANY SANITIZED

RECEIVED
OPPT/CBIC
98 AUG 20 AM 8:51

August 6, 1998
FMC Corporation
8EHQ-0498-14170S and 14171S

We understand this information to be responsive to the Agency's inquiry. If you require additional information, please feel free to contact me.

Sincerely yours,

A handwritten signature in cursive script that reads "Linda M. Clark".

Linda M. Clark
Product Regulatory Affairs Manager
215/299-6133